Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity


Sushrut Kamerkar, Charan Leng, olga Burenkovasu, Chul Jang, christine Mccoy, Kelvin, Zhang, Kevin Dooley, Samuel Kasera, Tong Zi, Sílvia Sisó, William Dahlberg, Chang Ling Sia, Shil Patel, Karl Schmidt, Kyriakos Economides, Timothy Soos, Dalia Burzyn And Sriram Sathyanarayanan


Effectiveness of checkpoint immunotherapy in cancer can be undermined by immunosuppressive tumor-associated macrophages (TAMs) with an M2 phenotype. Reprogramming TAMs toward a proinflammatory M1 phenotype is a novel approach to induce antitumor immunity. The M2 phenotype is controlled by key transcription factors such as signal transducer and activator of transcription 6 (STAT6), which have been “undruggable” selectively in TAMs. We describe an engineered exosome therapeutic candidate delivering an antisense oligonucleotide (ASO) targeting STAT6 (exoASO-STAT6), which selectively silences STAT6 expression in TAMs. In syngeneic models of colorectal cancer and hepatocellular carcinoma, exoASO-STAT6 monotherapy results in >90% tumor growth inhibition and 50 to 80% complete remissions. Administration of exoASO-STAT6 leads to induction of nitric oxide synthase 2 (NOS2), an M1 macrophage marker, resulting in remodeling of the tumor microenvironment and generation of a CD8 T cell–mediated adaptive immune response. Collectively, exoASO-STAT6 represents the first platform targeting transcription factors in TAMs in a highly selective manner.


SCIENCE ADVANCES • 18 Feb 2022 • Vol 8Issue 7 • DOI: 10.1126/sciadv.abj7002

Read the paper here